Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.

rhIL‑7-hyFc was not associated with improved survival in the overall cohort but was associated with improved survival in older patients. Adding rhIL‑7-hyFc, a long-acting IL-7, to treatment with ...

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Adding TTFields to first-line treatment with temozolomide and radiotherapy improved progression-free survival in patients with glioblastoma.

More than three-quarters of evaluable patients had a tumor-associated antigen-specific immune response. CVGBM, an investigational cancer vaccine, induced immune responses in more than three-quarters ...

In its accelerated approval decisions of new cancer drugs, the FDA might be underestimating the willingness of some patients ...

A CXB boost continues to provide an organ preservation benefit at 5 years, though there is some local regrowth after 3 years, ...

Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy — with or without epacadostat — ...

The disease control rate was 92%, and the median progression-free survival was 13.7 months. Treatment with 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and pembrolizumab appeared well ...

Study results “provide strong support for integrating symptom screening and care pathways into routine clinical care,” according to researchers ...